Enanta Pharmaceuticals Conference Call Summary Company Overview - Enanta Pharmaceuticals is a drug discovery and development company based in Watertown, Massachusetts, specializing in small molecule drug discovery, particularly in infectious diseases and virology [2][3]. Key Products and Developments - Enanta has developed two protease inhibitors for hepatitis C in collaboration with AbbVie: VIEKIRA PAK and MAVYRET, the latter being the only 8-week cure for chronic and acute hepatitis C, curing between 1 and 2 million patients globally [3]. - Current focus includes developing treatments for respiratory syncytial virus (RSV), with no approved treatments available to date [3][4]. - Enanta has initiated programs targeting immunology, including: - **KIT**: Aiming to deplete mast cells for conditions like urticaria [8][39]. - **STAT6**: Targeting the IL-4, IL-13 pathway, with a goal to create an oral alternative to Dupixent [47]. - **MRGPRX2**: Aiming to address mast cell-driven diseases and potentially migraines [56]. RSV Programs - Enanta is developing two RSV molecules: - **Zelicapavir**: A replication inhibitor that has shown a reduction in symptom duration by about 7 days compared to placebo, with a 50% reduction in hospitalization rates observed in phase 2 studies [17][18]. - **EDP-323**: A potent viral polymerase inhibitor that demonstrated faster viral load reduction in challenge studies, potentially offering better efficacy [20][22]. - Phase 3 studies for Zelicapavir are planned, focusing on high-risk adult populations [14]. Immunology Programs - The first immunology program targeting KIT is on track for an IND filing in Q1 and phase 1 data in Q4 [40]. - The STAT6 program is expected to file for IND in the second half of the year [54]. - MRGPRX2 is in prototype optimization, with plans to have a candidate ready in the second half of the year [60]. Financial Position - Enanta reported $242 million in cash at the end of the last quarter, providing a runway into fiscal 2029 [61]. Strategic Considerations - Enanta is considering partnerships for its RSV products, weighing the timing of partnerships against the potential value generated from phase 3 data [31][32]. - The company aims to maintain a leadership position in RSV treatment while exploring the potential of EDP-323 as a next-generation option [25][27]. Conclusion - Enanta Pharmaceuticals is actively advancing its pipeline in both virology and immunology, with significant potential in treating RSV and mast cell-related diseases. The company is well-capitalized to support its clinical programs and is strategically evaluating partnership opportunities to maximize the commercial potential of its assets [61].

Financial Status - Enanta Pharmaceuticals reported a strong balance sheet with $193.4 million in cash as of March 31, 2025[6] - The company is leveraging ongoing royalties to support its robust pipeline[6] Respiratory Syncytial Virus (RSV) - Zelicapavir (EDP-938) - Zelicapavir is the only N-inhibitor in clinical development for RSV[17] - A Phase 2 pediatric study showed a viral load decline of 1.18 log at Day 5 in a prespecified subset of patients[25] - A Phase 2 pediatric study showed a viral load decline of 1.4 log at the end of treatment in Part 2[30] - EDP-323, an RSV L-protein inhibitor, demonstrated an 85-87% reduction in viral load AUC in a human challenge model[42] Immunology - KIT Inhibitor (EPS-1421) - EPS-1421 inhibits KIT with nanomolar potency in both binding and cellular assays[63] - EPS-1421 exhibits greater than 500-fold selectivity for KIT over other KIT family members[68] - In mice, EPS-1421 inhibits SCF-mediated histamine release with an EC50 (free drug) of 0.25nM[65] Immunology - STAT6 Inhibitor - Prototype STAT6 inhibitors exhibit nanomolar inhibition in biochemical and cellular assays[84] - Prototype STAT6 inhibitor demonstrates good selectivity, with greater than 1000x biochemical selectivity for STAT6 over other STATs[88] - Prototype STAT6 oral inhibitor results in complete inhibition of pSTAT6 in a mouse model[93]